Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of **ascorbic acid** (vitamin C) and **reduced glutathione (GSH)**, both potent water-soluble antioxidants, primarily used for their additive and synergistic efficacy in neutralizing reactive oxygen species (ROS) and preventing oxidative damage in cells. This combination is under investigation, particularly in intravenous formulations, for its potential to prevent contrast-associated acute kidney injury (CA-AKI) in patients with acute myocardial infarction undergoing coronary interventions, based on the hypothesis that their combined use enhances ROS scavenging, promotes vasodilation through increased nitric oxide bioavailability, and improves tissue perfusion[1][2][7]. Oral and intravenous regimens are studied for reducing oxidative stress and for protective effects in hepatic and renal diseases[3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ascorbic acid + reduced glutathione.